Bumma Naresh, Papadantonakis Nikolaos, Advani Anjali S
Department of Internal Medicine, The Cleveland Clinic, Desk R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Department of Hematology/Oncology, Cleveland Clinic Lerner College of Medicine, The Cleveland Clinic, Desk R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Future Oncol. 2015;11(12):1729-39. doi: 10.2217/fon.15.84.
The treatment of acute lymphoblastic leukemia (ALL) in adults remains challenging and novel therapies are needed. The antigen, CD19, is expressed by >90% of pre-B ALLs and represents an attractive therapeutic target. The bispecific T-cell-engaging antibody, blinatumomab, targets CD19 and has demonstrated encouraging results in minimal residual disease positive and relapsed/refractory pre-B ALL. In this review, we discuss in detail the mechanism of action and key pharmacologic aspects of blinatumomab. In addition, the preclinical studies, clinical studies and toxicities are summarized.
成人急性淋巴细胞白血病（ALL）的治疗仍然具有挑战性，需要新的治疗方法。抗原CD19在超过90%的前B-ALL中表达，是一个有吸引力的治疗靶点。双特异性T细胞衔接抗体博纳吐单抗靶向CD19，在微小残留病阳性和复发/难治性前B-ALL中已显示出令人鼓舞的结果。在本综述中，我们详细讨论了博纳吐单抗的作用机制和关键药理学方面。此外，还总结了临床前研究、临床研究和毒性。
